Overview

NCI Definition [1]:
A preparation of formaldehyde-deactivated toxin isolated from the bacterium Clostridium tetani. Tetanus toxoid is used for booster injection and can stimulate the production of antitoxin antibodies. This agent may be used as an adjuvant in cancer vaccines.

Tetanus toxoid vaccine has been investigated in 3 clinical trials, of which 3 are open and 0 are closed. Of the trials investigating tetanus toxoid vaccine, 2 are phase 1/phase 2 (2 open) and 1 is phase 2 (1 open).

H3F3A K28M, HLA-A*02:01 Positive, and Hypodiploidy are the most frequent biomarker inclusion criteria for tetanus toxoid vaccine clinical trials.

Diffuse intrinsic pontine glioma, diffuse midline glioma, H3 K27M-mutant, and glioma are the most common diseases being investigated in tetanus toxoid vaccine clinical trials [2].

Top Biomarker Inclusion Criteria for Open Clinical Trials Investigating Tetanus Toxoid Vaccine
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating tetanus toxoid vaccine and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Synonyms [2]:
vaccine, tetanus, htig - tetanus vaccine, tetanus toxoid vaccine, inactivated, tetanus toxoid, tetanus toxoid [chemical/ingredient], tetanus vaccine, tetanus toxoid vaccine, tetanus toxoid, tt, clostridium tetani toxoid antigen (formaldehyde inactivated), tetanus vaccine, tetanus toxoid, clostridium tetani, tetanus toxoids, tetanus vaccine (product), tetanus toxoid, tetanus, toxoid, tetanus, tetanus vaccine (substance), tettox
NCIT ID [1]:
C2660
SNOMED ID [1]:
F-61EC7

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.